CBLN1 and Alzheimer disease: To test if efficient Cer trafficking from the ER to the Golgi is vital in the regulation of the Cer levels and Aβ formation, we administered the CERTs inhibitor N-(3-hydroxy-1-hydroxymethyl-3-phenylpropyl) dodecanamide (HPA-12) for 4 weeks to AD transgenic mice.